Navigation Links
CareFusion Reports Preliminary First Quarter Fiscal 2013 Results
Date:11/8/2012

>

97

93

4Other7

6

17Procedural Solutions4Infection Prevention 

$ 144

$ 138

4 %Medical Specialties

80

78

3Specialty Disposables

62

66

(6)Total Procedural Solutions

$ 286

$ 282

1OPERATING EXPENSES:Selling, General and Administrative Expenses

$ 244

$ 264

(8) %Research and Development Expenses

47

37

27Restructuring and Acquisition Integration Charges

2

7

(71)OTHER ITEMS:Interest Expense and Other, Net 

$ 20

$ 25

(20) %Loss from Discontinued Operations, Net of Tax

(5)

(2)

150WEIGHTED-AVERAGE NUMBER OF COMMON SHARES OUTSTANDING:Basic221.9

223.8Diluted224.4

226.3Adjusted Financial Measures:5Operating Expenses

$ 276

$ 279____________1

All results are preliminary and remain subject to the completion of the company's quarterly review and the filing of its Form 10-Q for the quarter ended Sept. 30, 2012, including the completion of the company's analysis regarding its Dispensing sales-type leases, as discussed above.2

Revenue for the Dispensing Technologies business unit intentionally omitted. As discussed above, until the analysis regarding the company's Dispensing sales-type leases is complete, the company is unable to report the financial results for its Dispensing Technologies business. 3

In July, 2012, the company began managing its Respiratory Diagnostics business as part of its Respiratory Technologies business unit within the Medical Systems reporting segment. Previously, the Respiratory Diagnostics business had been reported in Procedural Systems as Other. Prior period financials have been reclassified to conform to the current presentation.4

Reflects the impac
'/>"/>

SOURCE CareFusion Corp.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. CareFusion To Report Preliminary Fiscal 2013 First Quarter Results On Nov. 8
2. CareFusion Provides Update On Form 10-K Filing
3. CareFusion Recognizes Best Of The Best U.S. Hospitals
4. CareFusion Reports Fourth Quarter and Fiscal 2012 Results
5. CareFusion To Report Fourth Quarter And Fiscal 2012 Results On Aug. 9
6. CareFusion Expands Infusion Pump Interoperability
7. CareFusion Strengthens U.K. Presence With Acquisition of Medical Products Distributor
8. CareFusion to Sell Neurodiagnostic Business to Natus Medical for $58 Million
9. Verenium Reports Financial Results For The Third Quarter And Nine Months Ended September 30, 2012
10. NxStage Reports Record Revenue for the Third Quarter of Fiscal 2012
11. Discovery Labs Reports Third Quarter 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 Reportlinker.com announces that a new ... catalogue: PharmaPoint: Atopic ... Analysis to 2022 http://www.reportlinker.com/p01957657/PharmaPoint-Atopic-Dermatitis---India-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ... India Drug Forecast and Market Analysis to ...
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a leading ... of severely obese patients, today announced initial results ... selective inhibitor of methionine aminopeptidase 2 (MetAP2), in ... of genetic obesity.  These results showed improvements in ...
(Date:1/14/2014)... , Jan. 14, 2014 InformEx, North America,s ... of high-value chemistry, will hold the 30 th edition ... Convention Center from January 21-24. (Logo: ... from top pharmaceutical, fine chemical and specialty chemical companies will ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
(Date:4/22/2014)... influenced by low exposure to testosterone in the womb, ... men,s testosterone levels may be determined before they are ... the hormone than others is important because testosterone is ... hormone have been linked to obesity, diabetes and heart ... for producing testosterone in adults known as Leydig ...
(Date:4/22/2014)... fiction: In enemy territory, activate your cloaking device. And ... to the immune system. Now scientists at Harvard,s Wyss ... tactics to build the first DNA nanodevices that survive ... the way for smart DNA nanorobots that could use ... doctors can today; target drugs to tumors, or even ...
(Date:4/22/2014)... a clinical trial led by Dana-Farber Cancer Institute ... approved a molecularly targeted drug as second-line treatment ... standard chemotherapy has failed. , The FDA approval ... manufacturer, Lilly Oncology, of Indianapolis. A monoclonal antibody ... sold under the name Cyramza, and is the ...
(Date:4/22/2014)... the University of Toronto say a sleep disorder that ... best current predictor of brain diseases like Parkinson,s and ... not just a precursor but also a critical warning ... says associate professor and lead author Dr. John Peever. ... cent of people with RBD will develop a brain ...
(Date:4/21/2014)... Minn. Acute respiratory distress syndrome is a ... who develop the lung disorder postoperatively are at ... those who survive the syndrome may still bear ... Mayo Clinic-led study is helping physicians better identify ... preventing this dangerous and costly surgical complication. ...
Breaking Medicine News(10 mins):Health News:Cloaked DNA nanodevices survive pilot mission 2Health News:Cloaked DNA nanodevices survive pilot mission 3Health News:FDA approves first targeted drug for advanced stomach cancer 2Health News:Acute respiratory distress syndrome: Study IDs surgical patients at risk 2
... New York, NY (June 6, 2012) A clinical ... molecular therapy called vismodegib (trade name Erivedge), can dramatically ... of new ones, in patients with basal cell nevus ... sometimes hundreds or thousands, of skin cancers on each ...
... In a Phase 2 study presented at the ... Oncology (ASCO), clinical researchers from University Hospitals Case Medical ... to treat gynecologic cancers, shortening radiation treatment time from ... stereotactic body radiotherapy (SBRT), has been used on other ...
... THURSDAY, May 31 (HealthDay News) -- Live chicks and ducklings ... a salmonella outbreak that had sickened 93 people in 23 ... in an update Thursday. Eighteen people have been ... under investigation. Among the reported cases so far, illnesses surfaced ...
... , THURSDAY, May 31 (HealthDay News) -- Meat, ... associated with a fivefold increased risk of immediate gout flare-ups, ... arthritis that often first occurs in the big toe. Anecdotal ... but it hasn,t been clear whether they cause immediate attacks. ...
... , THURSDAY, May 31 (HealthDay News) -- More than ... new government report shows. "Untreated tooth decay is ... Dye, an epidemiologist at the U.S. Centers for Disease ... appears that we haven,t been able to make any ...
... Steven Reinberg HealthDay Reporter , THURSDAY, May 31 ... the United States may be infected with chronic hepatitis B ... come from countries in Asia and Africa, where regular vaccination ... "Hepatitis B is a common infection transmitted at birth or ...
Cached Medicine News:Health News:New drug found effective against rare form of basal cell skin cancer 2Health News:New drug found effective against rare form of basal cell skin cancer 3Health News:University Hospitals Case Medical Center experts present at ASCO Annual Meeting 2Health News:University Hospitals Case Medical Center experts present at ASCO Annual Meeting 3Health News:Ohio Mail-Order Hatchery Now Linked to Salmonella in 23 States 2Health News:Gout Flare-ups Rise Sharply With Certain Foods: Study 2Health News:1 in 5 Americans Has Untreated Cavities: CDC 2Health News:Hepatitis B Infection Rates in U.S. Higher Than Thought 2Health News:Hepatitis B Infection Rates in U.S. Higher Than Thought 3
Inquire...
Rapid Urease test for the presumptive identification of H. pylori in gastric mucosal biopsies...
... The QuickVue H.pylori gII test is a ... qualitative detection of IgG antibodies specific to ... whole blood. It utilizes a convenient, non-invasive, ... aid physicians in the diagnosis of H.pylori ...
... a visually read, qualitative immunochromatographic method for ... a bacterium that grows in the stomach ... and some gastric cancers. FlexSure HP, available ... serum samples, provides the physician with the ...
Medicine Products: